key: cord-0757217-xeuzi71l authors: hoque, a.; Rahman, M.; Parvez, S.; Imam, H.; Nahar, N.; Chowdhury, F. U. H. title: Comparative analysis of antibody production by mRNA 1273, AZD 1222 and BBIBP-CorV on elderly people suffering from different co-morbidity in Bangladesh date: 2021-11-15 journal: nan DOI: 10.1101/2021.11.15.21266338 sha: 918fde63942e51e5bc37854360a74ea1b3e9da6f doc_id: 757217 cord_uid: xeuzi71l Background: As the pandemic spread so quickly all over the world, the scientist did not get the right time to cover all age group populations for a vaccine trial. The elderly population is usually vulnerable for COVID-19 which was proven by different research work and focus was to save this group of people was the prime concern for every country of the world. Though vaccines that got emergency use authorization have proven their efficacy which one is better for elderly people suffering from different co-morbid conditions is still not established. In this study, we want to evaluate the antibody production by mRNA 1273, AZD 1222, and BBIBP-CorV in elderly people with different comorbidity. Method: We include 40 people in each group who have at least one comorbid condition and the total sample size was 120. The sample was taken from them before vaccination and 14 days after the second dose. Adverse event following immunization was recorded if any. Antibody measurement was done by ELISA method by using DiaSino SARS-CoV-2 S1 RBD IgG Quant. Result: Among 120 participants with an equal number of participants in each of the vaccine groups all of them were aged between 60-72 years, of whom 65% were males and 35 % were females. Anti S1 RBD IgG was detected among all the participants from each vaccine group after 14 days of taking their 2nd dose. A non-parametric multiple comparison test (Kruskal-Wallis test) of Anti S1 RBD IgG levels among three vaccine groups revealed significant differences (P-value <0.05) between groups. The IgG level was almost twice in the mRNA-1273 group compared to AZD1222 and BBIBP-CorV group. Conclusion: From this small sample size, we predicate that mRNA 1273 produces much higher anti-S1 RBD IgG than the other two vaccines. Every vaccine is safe and effective whose is approved by WHO. Calculative use of the vaccine may produce an outcome for the future as we are still way behind in the proper amount of vaccine production. group (mean 577.1± 44.33 AU/ml) compared to AZD1222(mean 308.5 ±37.91 AU/ml) and BBIBP-CorV group. From this small sample size, we predicate that mRNA 1273 produce much higher anti-S1 RBD IgG than the other two vaccines. Every vaccine is safe and effective whose is approved by WHO. Calculative use of the vaccine may produce an outcome for the future as we are still way behind in the proper amount of vaccine production. From research results, we know that elderly individuals with othercomorbidities such as hypertension, cardiovascular abnormalities, diabetes, cancer, and asthma are more severely affected with a higher rate of case mortality [1] [2] [3] [4] . Particularly, a higher prevalence of the disease is reported in individuals above 60 years of age 1, 5 . Besides, a retrospective study conducted on 85 fatal COVID-19 cases reported a median age of 65.8 years for diabetes, cardiopulmonary diseases, and hypertension comorbidities 6 . Moreover, both innate and adaptive immune systems are reportedly weakened in the elderly with co-morbid, and the possibility of underlying chronic diseases upsurges as age advances, leading to the higher acquisition of infections 7 . Studies have called attention to the agerelated reduction in vaccine efficacy, owing to a decline in the adaptive and inherent immune response. As the aging population is increasing globally, vaccine endeavors must take into consideration age-related issues to ensure successful control of infectious diseases, like COVID-19. These attempts are necessary to secure a healthier life for the elderly as life expectancy is increasing 8 . An effective vaccine must stimulate a broad T and B cell response, potentially overcoming the reduced immune function in the older population 9 . . CC-BY-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 15, 2021. ; In the interim guidelines for COVID-19 vaccines from Pfizer, Moderna, and AstraZeneca published by the WHO Strategic Advisory Group of Experts on Immunization (SAGE), it was recommended that all the three COVID-19 vaccines can be used for individuals with high-risk comorbidities 10 . In Bangladesh, from early February mass vaccination has started with AZD1222. In step by step mRNA1273, BBIBP-CorV started. In this study, we want to evaluate the effect of AZD1222, mRNA1273, BBIBP-CorV to produce antibodies in elderly people who have co-morbidities. This observational study was conducted at Sheikh Hasina National Institute of Burn and Plastic Surgery, Dhaka February 2021 to October 2021. We enrolled 40 participants in each group and 120 are total number for our study age range between 60 years and above. Participants' demographic data along with past SARS-COV-2 infection history and existing comorbidities were recorded using a structured questionnaire. Antibodies to the RBD of the S1 subunit of the viral spike protein (IgG) were performed from the plasma samples using a commercially available Anti-SARS-CoV-2 ELISA kit(DiaSino SARS-CoV-2 S1 RBD IgG Quant) as per instruction supplied by the manufacturer. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 15, 2021. ; https://doi.org/10.1101/2021.11.15.21266338 doi: medRxiv preprint Among 120 participants with equal number of participants in each of the vaccine groups all of them were aged between 60-72 years, of whom 65% were males and 35 % were females. Among three vaccine groups, 100% of the mRNA-1273 recipients, 62.5% of AZD1222 recipients and only 2.5% of BBIBP-CorV recipients had injection site pain. Fever as AEFI was found among 32.5% of AZD1222 recipients and 10% of BBIBP-CorV recipients. None of the mRNA-1273 recipients had any fever as AEFI (Table 1) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 15, 2021. ; disease 23 . Both mRNA and viral vector-based vaccines effectively produced TH1. IgG subclasses are important in producing antibodies. From the different studies, we have found that mRNA vaccines induce all classes of IgG whereas viral vector-based vaccine especially induces IgG1 and IgG3. Variability in somatic hyper-mutation could influence neutralization through antibody affinity maturation. The study has found that participants with elderly age have a low level of somatic hypermutation in class-switched B cell receptors (BCRs) than the younger group 10 . Neutralizing antibodies also waned overtime after the second dose of BNT162b2 or ChAdOx1 27 . From our study, we have found that after getting two doses of vaccine mRNA produced a much higher antibody than viral vector and inactivated vaccine. Whereas from AEFI data we have found that inactivated vaccines have fewer reports than others which is similar to published data [24] [25] [26] . This small sample size cannot produce generalizability. Therefore, subsequent clinical studies with larger sample sizes with different age group should be enclosed to confirm our findings. Moreover, only antibody response could not evaluate the efficacy of any vaccine, cellular response should be evaluated. COVID-19 vaccine is still produced by a few countries which can be counted by finger. A country like Bangladesh still depends on vaccine-producing countries and COVAX. Careful utilization of vaccines can be a possible way to prevent COVID-19 related death. Though our sample size is very small, from . CC-BY-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 15, 2021. ; Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China Clinical features of 85 fatal cases of COVID-19 from wuhan: a retrospective observational study Aging and the immune system: the impact of immunosenescence on viral infection, immunity and vaccine immunogenicity Covid-19 and immunity in aging populations-A new research agenda. Perspective Can an effective SARS-CoV-2 vaccine be developed for the older population? Immun Ageing Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2 Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant An mRNA vaccine against SARS-CoV-2 -preliminary report Durability of responses after SARS-CoV-2 mRNA-1273 vaccination Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial Clinical and immunological features of severe and moderate coronavirus disease 2019 Phenotype and kinetics of SARSCoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome SARS-CoV-2 responsive T cell numbers are associated with protection from COVID-19: a prospective cohort study in keyworkers An mRNA vaccine against SARS-CoV-2 -preliminary report Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Spike-antibody waning after second dose of BNT162b2 or ChAdOx1 our study we can find that mRNA 1273 is best protective for the elderly population with different co-morbidity. Every vaccine is safe and effective whose is approved by WHO. Calculative use of the vaccine may produce outcomes for the future as we are still way behind in the proper amount of vaccine production. The authors have declared no competing interests. No external funding was received. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.